FilingSEC EDGAR10-Q
Standard BioTools to Merge with Treeline and Divest Mass Cytometry Business
· SEC accepted
StageIn progress
Filing content
The company expects to close its merger with Treeline in the fourth quarter of 2026 and has entered into an agreement to sell its mass cytometry business for $5.5 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…